Compare RUM & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUM | PTGX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 9.5B |
| IPO Year | 2021 | 2016 |
| Metric | RUM | PTGX |
|---|---|---|
| Price | $9.47 | $150.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $108.23 |
| AVG Volume (30 Days) | ★ 4.1M | 451.6K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.72 | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | ★ $100,622,320.00 | N/A |
| Revenue This Year | $209.98 | $874.25 |
| Revenue Next Year | $40.99 | N/A |
| P/E Ratio | ★ N/A | $63.62 |
| Revenue Growth | ★ 5.38 | N/A |
| 52 Week Low | $4.62 | $57.45 |
| 52 Week High | $10.60 | $160.81 |
| Indicator | RUM | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 70.60 | 56.62 |
| Support Level | $5.37 | $94.48 |
| Resistance Level | $10.54 | $160.81 |
| Average True Range (ATR) | 0.75 | 5.41 |
| MACD | 0.24 | -0.95 |
| Stochastic Oscillator | 76.92 | 24.89 |
RUM Group Inc focused is to maximize the power of human imagination through an independent technology ecosystem built on privacy, resilience, and an open alternative to Big Tech. Rumble gives human creativity a voice, a video and media platform built for creators and audiences who value free expression. Quake AI is a cloud and AI-infrastructure business, delivering the compute, data-center capacity, and blockchain infrastructure for the agentic era.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.